Sara Rundquist
6PUBLICATIONS
8CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Jul 12, 2024
Comparative Risk of Serious Infection With Vedolizumab vs Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease: Results From Nationwide Swedish Registers.Sara Karlqvist, Michael C Sachs, Carl Eriksson
|Apr 08, 2021
Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply.Sara Rundquist, Michael C Sachs, Carl Eriksson
|Feb 10, 2021
Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game-authors' reply.Sara Rundquist, Michael C Sachs, Carl Eriksson
|Dec 19, 2020
Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.Sara Rundquist, Michael C Sachs, Carl Eriksson
|Oct 25, 2018
Clinical effectiveness of golimumab in Crohn's disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).Sara Rundquist, Carl Eriksson, Linda Nilsson
Pageof 1
